United States - English - NLM (National Library of Medicine)

sincerus florida, llc - tazarotene (unii: 81bdr9y8ps) (tazarotene - unii:81bdr9y8ps), hyaluronate sodium (unii: yse9ppt4th) (hyaluronic acid - unii:s270n0trqy) -

United States - English - NLM (National Library of Medicine)

sincerus florida, llc - tazarotene (unii: 81bdr9y8ps) (tazarotene - unii:81bdr9y8ps), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4) -

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - tazarotene, quantity: 0.1 % w/w - foam - excipient ingredients: purified water; light liquid paraffin; diisopropyl adipate; ceteareth-12; potassium sorbate; sorbic acid; potassium citrate; butylated hydroxytoluene; citric acid; propane; butane; isobutane - for the topical treatment of acne vulgaris in patients 12 years of age or older.

New Zealand - English - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - tazarotene 0.5 mg/g - topical cream - 0.5 mg/g - active: tazarotene 0.5 mg/g excipient: benzyl alcohol carbomer carbomer 934p disodium edetate dihydrate light liquid paraffin medium-chain triglycerides purified water sodium hydroxide sodium thiosulfate pentahydrate sorbitan oleate - for the topical treatment of plaque psoriasis.

New Zealand - English - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - tazarotene 1 mg/g - topical cream - 1 mg/g - active: tazarotene 1 mg/g excipient: benzyl alcohol carbomer carbomer 934p disodium edetate dihydrate light liquid paraffin medium-chain triglycerides purified water sodium hydroxide sodium thiosulfate pentahydrate sorbitan oleate - for the topical treatment of plaque psoriasis.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

allergan ltd - tazarotene - cutaneous gel - 500microgram/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

allergan ltd - tazarotene - cutaneous gel - 1mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - tazarotene - cutaneous gel - 500microgram/1gram

United States - English - NLM (National Library of Medicine)

ipsen biopharmaceuticals, inc. - palovarotene (unii: 28k6i5m16g) (palovarotene - unii:28k6i5m16g) - sohonos is indicated for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (fop). sohonos is contraindicated in the following patients: - during pregnancy [see warnings and precautions (5.1) and use in specific populations (8.1)] . - a history of allergy or hypersensitivity to retinoids, or to any component of sohonos. anaphylaxis and other allergic reactions have occurred with other retinoids. [see description (11)]. risk summary sohonos is contraindicated during pregnancy. based on the findings in animal studies and class effects of retinoids, sohonos can cause fetal harm when administered during pregnancy [see warnings and precautions (5.1) and use in specific populations (8.3)] . in animal reproduction studies, oral administration of palovarotene to pregnant rats during the period of organogenesis resulted in multiple fetal malformations typical of retinoids

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - palovarotene, quantity: 1 mg - capsule, hard - excipient ingredients: croscarmellose sodium; sodium lauryl sulfate; lactose monohydrate; microcrystalline cellulose; povidone; magnesium stearate; titanium dioxide; potable water; gelatin; propylene glycol; butan-1-ol; purified water; isopropyl alcohol; shellac; ethanol absolute; iron oxide black; ammonia; potassium hydroxide - sohonos is indicated to reduce the formation of heterotopic ossification in adults and children aged 8 years and above for females and 10 years and above for males with fibrodysplasia ossificans progressiva (fop).